Edwards Lifesciences announced Thursday that the California company has completed three first-in-human implants of the company’s transcatheter mitral valve replacement system. But it is not the only ...
Edwards Lifesciences won FDA approval for SAPIEN M3, the first transseptal TMVR for mitral regurgitation. EW's system targets patients unable to undergo surgery or edge-to-edge repair by using a ...
After snaring the U.S. FDA’s approval for the Evoque tricuspid valve device, Edwards Lifesciences Corp. petitioned the Centers for Medicare & Medicaid Services for a national coverage determination ...
Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making it the first minimally invasive, catheter-based treatment that uses a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results